BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25935535)

  • 1. Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer.
    Feng X; Li H; Dean M; Wilson HE; Kornaga E; Enwere EK; Tang P; Paterson A; Lees-Miller SP; Magliocco AM; Bebb G
    Breast Cancer Res; 2015 May; 17(1):65. PubMed ID: 25935535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
    Abdel-Fatah TM; Arora A; Alsubhi N; Agarwal D; Moseley PM; Perry C; Doherty R; Chan SY; Green AR; Rakha E; Ball G; Ellis IO; Madhusudan S
    Neoplasia; 2014 Nov; 16(11):982-91. PubMed ID: 25425972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer.
    Feng X; Li H; Kornaga EN; Dean M; Lees-Miller SP; Riabowol K; Magliocco AM; Morris D; Watson PH; Enwere EK; Bebb G; Paterson A
    Oncotarget; 2016 Dec; 7(52):85798-85812. PubMed ID: 27741524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC.
    Petersen LF; Klimowicz AC; Otsuka S; Elegbede AA; Petrillo SK; Williamson T; Williamson CT; Konno M; Lees-Miller SP; Hao D; Morris D; Magliocco AM; Bebb DG
    Oncotarget; 2017 Jun; 8(24):38326-38336. PubMed ID: 28418844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
    Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
    Bozhanov SS; Angelova SG; Krasteva ME; Markov TL; Christova SL; Gavrilov IG; Georgieva EI
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1657-69. PubMed ID: 20177704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.
    Miller P; Kidwell KM; Thomas D; Sabel M; Rae JM; Hayes DF; Hudson BI; El-Ashry D; Lippman ME
    Breast Cancer Res Treat; 2017 Nov; 166(1):85-94. PubMed ID: 28717852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.
    Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
    Breast Cancer Res Treat; 2016 Jul; 158(2):233-41. PubMed ID: 27329169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
    Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.
    Bueno RC; Canevari RA; Villacis RA; Domingues MA; Caldeira JR; Rocha RM; Drigo SA; Rogatto SR
    Ann Oncol; 2014 Jan; 25(1):69-75. PubMed ID: 24285016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
    Albarakati N; Abdel-Fatah TM; Doherty R; Russell R; Agarwal D; Moseley P; Perry C; Arora A; Alsubhi N; Seedhouse C; Rakha EA; Green A; Ball G; Chan S; Caldas C; Ellis IO; Madhusudan S
    Mol Oncol; 2015 Jan; 9(1):204-17. PubMed ID: 25205036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of ATM protein in uveal melanoma and its association with clinicopathological factors.
    Jha J; Singh MK; Singh L; Pushker N; Bajaj MS; Sen S; Kashyap S
    Int J Clin Oncol; 2019 Dec; 24(12):1526-1535. PubMed ID: 31377937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
    Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
    Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
    Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
    Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.
    Rondeau S; Vacher S; De Koning L; Briaux A; Schnitzler A; Chemlali W; Callens C; Lidereau R; Bièche I
    Br J Cancer; 2015 Mar; 112(6):1059-66. PubMed ID: 25742469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct nuclear receptor expression in stroma adjacent to breast tumors.
    Knower KC; Chand AL; Eriksson N; Takagi K; Miki Y; Sasano H; Visvader JE; Lindeman GJ; Funder JW; Fuller PJ; Simpson ER; Tilley WD; Leedman PJ; Graham J; Muscat GE; Clarke CL; Clyne CD
    Breast Cancer Res Treat; 2013 Nov; 142(1):211-23. PubMed ID: 24122391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.